Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share Dump

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Jan 28, 2021 10:19am

166 Views

Post# 32408646

RE:Share Dump

Yea that was my thinking yesterday. Massive drop yesterday on not enough volume to warrant it, someone must have been desperate to get out. Remember 106k today is more than 1 million before the consoloidation and we didn't see that volume for long stretched last year.

<< Previous

Bullboard Posts

Next >>

Does Canada have any companies in the computer chip industry?